Evotec Reports Strong 2025 Financial Results Amid Transformation

Evotec SE announced its financial results for Q4 and full-year 2025, highlighting strong performance at the high end of guidance, with group revenues reaching €788.4 million. The company emphasized robust execution across key partnerships, notably with Bristol Myers Squibb and Bayer, and highlighted milestone achievements. The 'Just – Evotec Biologics' segment was noted for its contributions to growth, with significant transactions and agreements, including a landmark deal with Sandoz.

In 2025, Evotec advanced its Horizon operating model, aiming for €75 million in cost savings by 2027. The appointment of Dr. Ashiq H. Khan as Chief Commercial Officer signals a strengthened approach to commercial execution. The company anticipates 2026 as a transitional year with expected revenues between €700-780 million and adjusted EBITDA of €0-40 million.

Moving forward, Evotec's strategy includes operating model enhancements and continued emphasis on its commercial and scientific capabilities, with an outlook toward stronger financial performance by 2027 and beyond.